Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06306963
Other study ID # 23-004669
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 22, 2024
Est. completion date September 1, 2026

Study information

Verified date April 2024
Source Mayo Clinic
Contact Taylor N Hines
Phone 507-538-9959
Email hines.taylor@mayo.edu
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The researchers are trying to find out more about Gastric Antral Vascular Ectasia (GAVE). This is a condition that affects the blood vessels in the stomach, leading to their enlargement and possible bleeding. It can also cause symptoms such as abdominal pain and nausea. By participating in this study, you will help us learn how often these symptoms occur and how they relate to stomach functioning.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 1, 2026
Est. primary completion date March 1, 2026
Accepts healthy volunteers No
Gender All
Age group 19 Years and older
Eligibility Inclusion Criteria: - Patients >18 years of age with endoscopic evidence of Gastric Antral Vascular Ectasia. - Willingness to participate in the study - Capacity to provide informed consent. - No evidence of organic, systemic, or metabolic disease (e.g. diabetes mellitus) to explain the symptoms on routine investigations Exclusion Criteria: - Patients with active bleeding. - Patients with severe decompensated liver disease. - Patients with chronic kidney disease. - Presence of other diseases (structural or metabolic) which could interfere with interpretation of the study results. - Pregnant or lactating women due to radiation exposure.

Study Design


Related Conditions & MeSH terms


Intervention

Diagnostic Test:
Gastric Emptying
Measured by radioscintigraphy after overnight fast using a radiolabeled meal consisting of two 99mTc - labeled scrambled eggs, one slice of whole wheat bread and one glass of 111In DTPA skim milk (320kcal, 30% fat). A variable region of interest program will be used to quantitate counts in the stomach. Data will be summarized as GE T1/2 and GE % emptied at 1, 2 and 4 hours. To assess gastric emptying, the protocol meal as described above will be given. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. Scans will then be done at time 0 subsequently in 15-minute intervals to 90 minutes, then in 30-minute intervals thereafter to 240 minutes supine.

Locations

Country Name City State
United States Mayo Clinic Rochester Minnesota

Sponsors (1)

Lead Sponsor Collaborator
Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Abridged Bowel Disease Questionnaire The Abridged Bowel Disease Questionnaire is a 16-item questionnaire that measures Bowel Disease symptoms. Each item is scored as yes or no. Scores answering yes indicate more bowel disease, and scores answering no indicate less or no bowel disease. baseline
Primary Nepean Dyspepsia Index The Nepean Dyspepsia Index is a 10-item questionnaire that measures dyspepsia problems. Each item is scored from 1-5. 1 = Not at all, 5 = Extremely. Total scores range from 10 - 50, lower scores indicate less dyspepsia problems, higher scores indicate more dyspepsia problems. baseline
Primary Leuven Postprandial Distress Scale The Leuven Postprandial Distress Scale is an 8-item questionnaire that measures symptoms of dyspepsia. Each item is scored from 1-5. 1 = Absent, 5 = very severe. Total scores range from 0-40 Lower scores indicate less or no symptoms of dyspepsia, higher scores indicate more symptoms of dyspepsia. baseline
Secondary Gastric Emptying Half Time (T 1/2) of Solids Subjects will ingest a radio labeled meal consisting of two 99mTc. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. 1 hour, 2 hours, 4 hours
Secondary Gastric Emptying Half Time (T 1/2) of liquids Subjects will ingest one glass of 111In DTPA skim milk. Anterior and posterior scans of the abdomen, each of two minutes duration, will be obtained right after the meal is ingested to ensure adequate acquisition of counts. 1 hour, 2 hours, 4 hours
See also
  Status Clinical Trial Phase
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05014594 - Sodium-glucose Linked Transporter 2 (SGLT-2) Inhibitors in Recurrent Ascites: a Pilot RCT Phase 2
Not yet recruiting NCT03631147 - The Effect of Rifaximin on Portal Vein Thrombosis N/A
Completed NCT04939350 - Evaluation of the Vaccination Coverage of Cirrhotic Patients Followed in the General Hospitals in France in 2021
Completed NCT02528760 - To Determine the Role of Prokinetics in Feed Intolerance in Critically Ill Cirrhosis N/A
Recruiting NCT05484206 - Effect of Hepatic Impairment on the Pharmacokinetics and Safety of VIR-2218 and VIR-3434 Phase 1
Not yet recruiting NCT05538546 - Baveno VI Criteria in Dynamic Monitoring of High-risk Varices in Compensated Cirrhotic Patients
Not yet recruiting NCT04053231 - Hepatocarcinoma Recurrence on the Liver Study - Part2
Recruiting NCT02983968 - Use of the French Healthcare Insurance Database
Completed NCT02705534 - Sofosbuvir, Ledipasvir, Ribavirin for Hepatitis C Cirrhotics, Genotype 1 Phase 3
Completed NCT02596880 - Sofosbuvir, Daclatasvir, Ribavirin for Hepatitis C Virus (HCV) Cirrhotics Phase 3
Completed NCT02247414 - Warfarin Prevents Portal Vein Thrombosis in Patients After Laparoscopic Splenectomy and Azygoportal Disconnection Phase 4
Completed NCT02016196 - Rifaximin vs Placebo for the Prevention of Encephalopathy in Patients Treated by TIPS Phase 3
Withdrawn NCT01956864 - Study of High-Dose Oral Vitamin D for the Prevention of Liver Cancer Phase 1
Completed NCT02113631 - Comparative Effectiveness and Tolerability of Boceprevir vs Telaprevir N/A
Completed NCT01447537 - Mechanisms Involved in the Benefits of an Exercise Programme in Patients With Cirrhosis N/A
Completed NCT01362855 - Advance Care Planning Evaluation in Hospitalized Elderly Patients
Active, not recruiting NCT01205074 - ¹³C-Methacetin Breath Test (MBT) Methodology Study Phase 2/Phase 3
Completed NCT01476995 - Prognostic Indicators as Provided by the EPIC ClearView N/A
Completed NCT01231828 - Method of Assessment of Driving Ability in Patients Suffering From Wakefulness Pathologies. N/A